全文获取类型
收费全文 | 919篇 |
免费 | 86篇 |
国内免费 | 44篇 |
专业分类
儿科学 | 20篇 |
妇产科学 | 9篇 |
基础医学 | 45篇 |
临床医学 | 34篇 |
内科学 | 606篇 |
神经病学 | 4篇 |
特种医学 | 16篇 |
外科学 | 108篇 |
综合类 | 77篇 |
预防医学 | 21篇 |
药学 | 38篇 |
中国医学 | 12篇 |
肿瘤学 | 59篇 |
出版年
2023年 | 12篇 |
2022年 | 7篇 |
2021年 | 10篇 |
2020年 | 3篇 |
2019年 | 3篇 |
2018年 | 17篇 |
2017年 | 20篇 |
2016年 | 30篇 |
2015年 | 24篇 |
2014年 | 30篇 |
2013年 | 40篇 |
2012年 | 57篇 |
2011年 | 93篇 |
2010年 | 41篇 |
2009年 | 41篇 |
2008年 | 53篇 |
2007年 | 62篇 |
2006年 | 74篇 |
2005年 | 60篇 |
2004年 | 62篇 |
2003年 | 73篇 |
2002年 | 62篇 |
2001年 | 30篇 |
2000年 | 11篇 |
1999年 | 18篇 |
1998年 | 23篇 |
1997年 | 12篇 |
1996年 | 7篇 |
1995年 | 14篇 |
1994年 | 11篇 |
1993年 | 6篇 |
1992年 | 5篇 |
1991年 | 13篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1984年 | 3篇 |
1979年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有1049条查询结果,搜索用时 31 毫秒
1.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
2.
胃肠道黏膜屏障与自身免疫性疾病 总被引:4,自引:0,他引:4
肠黏膜具有免疫和屏障功能。一方面,消化道黏膜不断地与病毒、细菌等微生物接触,在机体内担负起第一线的局部防御任务。另一方面,该系统对于食源性抗原、肠内常驻细菌可以产生免疫耐受。此种识别机制是由一个特殊的肠黏膜免疫组织“肠相关淋巴样组织”(gut associated lymphoidtissue,GALT)承担的。 相似文献
3.
4.
目的 总结Wilson’s病患者亲体肝移植和全肝移植术后血清铜蓝蛋白及尿铜水平的恢复情况。方法 自 2 0 0 0年 9月至 2 0 0 3年 11月我院为 2 6例Wilson’s病患者施行了肝移植术 ,均并发终末期肝硬变 ,其中 3例发生急性肝功能衰竭。术前血清铜蓝蛋白和尿铜水平分别为 (12 4 .8± 2 2 .8)mg/L和 (15 2 4 .8± 32 8.6 ) μg/ 2 4h ,其中行活体部分肝移植 2 2例 ,全肝移植 4例 ,亲体肝移植供体术前血清铜蓝蛋白水平为 (2 30 .4± 2 9.6 )mg/L ,尿铜水平均 <5 0μg/ 2 4h。结果 所有患者手术顺利 ,全肝移植患者术后 1、3、6及 12个月血清铜蓝蛋白和尿铜水平分别为 (32 0 .2±36 .8)mg/L、(380 .4± 4 5 .6 )mg/L、(36 0 .5± 37.6 )mg/L、(35 6 .2± 2 7.6 )mg/L和 (2 4 0 .4± 2 2 .8) μg/ 2 4h、(86 .5± 10 .6 ) μg/ 2 4h、(5 4 .2± 6 .8) μg/ 2 4h及 (46 .8± 3.4 ) μg/ 2 4h ;亲体肝移植患者术后 1、3、6及 12个月血清铜蓝蛋白和尿铜水平分别为 (2 16 .8± 2 0 .4 )mg/L、(2 4 8.5± 32 .6 )mg/L、(2 85 .4± 4 4 .3)mg/L、(2 6 0 .2± 36 .6 )mg/L和(380 .8± 37.6 ) μg/ 2 4h、(15 0 .6± 2 4 .5 ) μg/ 2 4h、(75 .5± 9.6 ) μg/ 2 4h及 (6 0 .3± 5 .8) μg/ 2 4h。结论 全肝移植和亲体肝 相似文献
5.
目的观察α-干扰素(IFN-α)治疗肝癌产生耐药性的过程,探讨其机制。方法裸鼠肝内原位接种裸鼠人肝癌高转移裸鼠模型LCI-D20肿瘤组织,随机分为7组,每组6只。其中治疗组于接种肿瘤后第2天皮下注射给予IFN-α(1.5×10~7 U/kg体重/d)20 d,治疗组A和B裸鼠于停药后第1和21天分别被处死;治疗组C和D于停药后第21天再次给予同剂量IFN-α(1.5×10~7 U/kg体重/d)联合格列卫(100mg/kg体重/d,灌胃)治疗20 d。对照组E~G分别在接种肿瘤后第28、48、68天被处死。观察裸鼠体重,肿瘤大小、体积,检测血清血管内皮细胞生长因子(VEGF)浓度、肿瘤组织微血管密度。抽提A、D、E、G各组总RNA做关于血管生成SuperArray基因芯片。结果A~G组肿瘤的大小分别为0.27、1.54、3.22、2.23、0.68、1.93、3.98 g,其中组A和组E,组D和组G相比,肿瘤大小差异有统计学意义(P<0.05)。外周血VEGF浓度组A和组E,组C、D和组G相比差异有统计学意义(P<0.05)。芯片结果提示在IFN-α治疗过程中,肝癌组织VEGF mRNA和裸鼠血清中的VEGF仍保持较低水平,而PDGF-AA mRNA的表达水平逐渐升高。组A微血管密度显著低于组E,而在组C和组G间差异无统计学意义。HE染色显示治疗组与对照组相比,异常核分裂象增多,肿瘤周围包膜变薄,纤维成分减少。结论肝癌可对IFN-α治疗产生耐药性,可能的机制为肝癌肿瘤血管生成由VEGF依赖转化为PDGF依赖。 相似文献
6.
7.
8.
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure 总被引:9,自引:0,他引:9
Yancy CW Fowler MB Colucci WS Gilbert EM Bristow MR Cohn JN Lukas MA Young ST Packer M;U.S. Carvedilol Heart Failure Study Group 《The New England journal of medicine》2001,344(18):1358-1365
BACKGROUND: The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure. METHODS: In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients. RESULTS: As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P> 0.05 in all analyses). CONCLUSIONS: The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure. 相似文献
9.
Dr. Gennaro D'amico MD Alberto Morabito MS Luigi Pagliaro MD Ettore Marubini MD The Liver Study Group of “V. Cervello” Hospital 《Digestive diseases and sciences》1986,31(5):468-475
Six-year survival of cirrhosis was assessed in a series of 1155 consecutive patients (751 men, 404 women). Among the men, 33% were alcoholics and 18% were HBsAg positive; corresponding figures for the women were 15% and 6%, respectively. Features of decompensation at first presentation were observed in 63% of the patients. Six-year survival was 54% in compensated and 21% in decompensated patients. No significant differences in survival were found between alcoholics and nonalcoholics. Leading causes of death were liver failure (49%), hepatocellular carcinoma (22%), and bleeding (13%). The prognostic role of 21 variables was evaluated separately in compensated and decompensated patients by the Cox's regression model. The following variables were found to be significant predictors of death risk in compensated patients: male sex, HBsAg positivity, age, prothrombin time prolongation, and esophageal varices. In decompensated disease the significant indicators of death risk were: hepatocellular carcinoma, encephalopathy, hemorrhage, SGOT, esophageal varices, gamma globulins, prothrombin time prolongation, continued abuse of alcohol, HBsAg positivity, gamma glutamyl transpeptidase, and cholinesterase. A simple prognostic index based upon the relative risk coefficient of the significant variables is suggested.Members of the Liver Study Group are: Maria Caltagirone, Gabriella Filippazzo, Giovanni Gatto, Gandolfo Giannuoli, Silvio Margin, Guiseppe Malizia, Lorenzo Maniaci, Maria Pia Marcenó, Alberto Maringhini, Rocco Micciolo, Salvatore Orsini, Fabio Pace, Ugo Palazzo, Linda Pasta, Giuseppina Russo, Rosa Giovanna Simonetti, Mario Spinello, Mario Traina, Mario Valenza, Maria Vinci, Giovanni Vizzini. 相似文献
10.
Isabel M. A. Brüggenwirth Maureen J. M. Werner René Adam Wojciech G. Polak Vincent Karam Michael A. Heneghan Arianeb Mehrabi Jürgen L. Klempnauer Andreas Paul Darius F. Mirza Johann Pratschke Mauro Salizzoni Daniel Cherqui Michael Allison Olivier Soubrane Steven J. Staffa David Zurakowski Robert J. Porte Vincent E. de Meijer all the other contributing centers the European Liver Intestine Transplant Association 《Transplant international》2021,34(10):1928-1937
High-risk combinations of recipient and graft characteristics are poorly defined for liver retransplantation (reLT) in the current era. We aimed to develop a risk model for survival after reLT using data from the European Liver Transplantation Registry, followed by internal and external validation. From 2006 to 2016, 85 067 liver transplants were recorded, including 5581 reLTs (6.6%). The final model included seven predictors of graft survival: recipient age, model for end-stage liver disease score, indication for reLT, recipient hospitalization, time between primary liver transplantation and reLT, donor age, and cold ischemia time. By assigning points to each variable in proportion to their hazard ratio, a simplified risk score was created ranging 0–10. Low-risk (0–3), medium-risk (4–5), and high-risk (6–10) groups were identified with significantly different 5-year survival rates ranging 56.9% (95% CI 52.8–60.7%), 46.3% (95% CI 41.1–51.4%), and 32.1% (95% CI 23.5–41.0%), respectively (P < 0.001). External validation showed that the expected survival rates were closely aligned with the observed mortality probabilities. The Retransplantation Risk Score identifies high-risk combinations of recipient- and graft-related factors prognostic for long-term graft survival after reLT. This tool may serve as a guidance for clinical decision-making on liver acceptance for reLT. 相似文献